Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against Acinetobacter baumannii-calcoaceticus complex strains isolated from respiratory and bloodstream sources: results from ACNBio study
Antimicrobial Agents and Chemotherapy · 06.08.2025 · 69 (8)
DOI: 10.1128/aac.00379-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.08.2025. Verfasst von Ecem Buyukyanbolu und 33 weiteren Autor:innen. Beteiligte Einrichtung: Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA. Hauptthemen laut MEDLINE: Sulbactam, Anti-Bacterial Agents, Acinetobacter baumannii, Ampicillin. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Infections caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (ABC) are associated with high mortality rates and limited treatment options. This study aims to evaluate the in vitro activity of clinically utilized antimicrobials against a contemporary collection of ABC isolates with a predominant carbapenem-resistant phenotype. Geographically dispersed US medical centers ( n = 22) provided non-duplicate respiratory and bloodstream ABC isolates for surveillance testing. Antimicrobial susceptibility testing was conducted by broth microdilution and interpreted according to Clinical & Laboratory Standards Institute (CLSI) and Food and Drug Administration (FDA) breakpoints. ABC isolates ( n = 523) from respiratory tract (74.4%) and blood (25.6%) sources were recovered from patients (2023–2024). Forty percent were obtained from intensive care unit patients. Carbapenem non-susceptibility was observed in 76.9% of isolates and was more common among respiratory tract cultures. The addition of durlobactam to sulbactam decreased the MIC 90 by three-doubling dilutions from 32 to 4 µg/mL, increasing the susceptibility rate to 96.9% from 33.8%. Genome sequencing of sulbactam-durlobactam non-susceptible isolates (16/523; n = 3.1%) revealed MBL and non-enzymatic resistance mechanisms. Cefiderocol inhibited 93.5% and 76.1% of isolates at CLSI and FDA susceptible breakpoints, respectively. Minocycline susceptibility was
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
- Advocate Lutheran General Hospital, Park Ridge, Illinois, USA.
- Department of Microbiology, ACL Laboratories, Milwaukee, Wisconsin, USA.
- Department of Pathology, Saint Louis University School of Medicine, St. Louis, Missouri, USA.
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Froedtert & Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
ORCID-Profile: Eric T Beck, Romney M Humphries, Holly Huse, Wesley D Kufel, Navaneeth Narayanan, Patricia J Simner, Robert J Tibbetts, Lilian M Abbo, Rebekah E Dumm, David P Nicolau, Tomefa E Asempa
Zitieren
APA
Buyukyanbolu, E., Argotsinger, J., Beck, E. T., Chamberland, R. R., Clark, A. E., Daniels, A. R., Liesman, R., Fisher, M., Gialanella, P., Hand, J., Harrington, A. T., Humphries, R. M., Huse, H., Hamilton-Seth, R., Hankins, J. D., Kufel, W. D., Riddell, S. W., Marino, J., Westblade, L. F., …, & Acinetobacter baumannii Complex National Biorepository (ACNBio) Study Group (2025). Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against Acinetobacter baumannii-calcoaceticus complex strains isolated from respiratory and bloodstream sources: results from ACNBio study. Antimicrobial Agents and Chemotherapy, 69(8). https://doi.org/10.1128/aac.00379-25
Vancouver
Buyukyanbolu E, Argotsinger J, Beck ET, Chamberland RR, Clark AE, Daniels AR, et al. Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against Acinetobacter baumannii-calcoaceticus complex strains isolated from respiratory and bloodstream sources: results from ACNBio study. Antimicrobial Agents and Chemotherapy. 2025;69(8). doi:10.1128/aac.00379-25
BibTeX
@article{Buyukyanbolu2025,
author = {Buyukyanbolu, Ecem and Argotsinger, Jill and Beck, Eric T and Chamberland, Robin R and Clark, Andrew E and Daniels, Anne R and Liesman, Rachael and Fisher, Mark and Gialanella, Philip and Hand, Jonathan and Harrington, Amanda T and Humphries, Romney M and Huse, Holly and Hamilton-Seth, Robert and Hankins, Julia D and Kufel, Wesley D and Riddell, Scott W and Marino, Jamie and Westblade, Lars F and Mochon, A Brian and Narayanan, Navaneeth and Kirn, Thomas J and Pierce, Virginia M and Potula, Raghava and Tekle, Tsigereda and Simner, Patricia J and Tibbetts, Robert J and Vu, Christine and Abbo, Lilian M and Martinez, Octavio and Dumm, Rebekah E and Nicolau, David P and Asempa, Tomefa E and Acinetobacter baumannii Complex National Biorepository (ACNBio) Study Group, Acinetobacter baumannii Complex National Biorepository (ACNBio) Study Group},
title = {Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against Acinetobacter baumannii-calcoaceticus complex strains isolated from respiratory and bloodstream sources: results from ACNBio study},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {8},
doi = {10.1128/aac.00379-25}
}
EUVIMED